Associated Papers
Gain-of-Function Variant TRPC6 A404V Is Associated With Doxorubicin-Related Cardiomyopathy.
Wu Y et al.
Circulation. Genomic and Precision Medicine, 2026
Genetic landscape and therapeutic evolution of cyclophosphamide: spotlight on breast cancer.
Cao J et al.
Journal of Chemotherapy (florence, Italy), 2025
Role of genetic modifiers on pulmonary consequences of cancer therapy in children.
Dobkin SL et al.
Scientific Reports, 2025
SNP's use as a potential chemotoxicity stratification tool in breast cancer: from bench to clinic.
Moustafa HAM et al.
Functional & Integrative Genomics, 2025
Proteogenomic Profiling of Treatment-Naïve Metastatic Malignant Melanoma.
Kuras M et al.
Cancers, 2025
The biomedical relationship corpus of the BioRED track at the BioCreative VIII challenge and workshop.
Islamaj R et al.
Database : the Journal of Biological Databases and Curation, 2024
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
Pharmacogenomics for Prediction of Cardiovascular Toxicity: Landscape of Emerging Data in Breast Cancer Therapies.
Altena R et al.
Cancers, 2022
Novel molecular biomarkers of cancer therapy-induced cardiotoxicity in adult population: a scoping review.
Cartas-Espinel I et al.
Esc Heart Failure, 2022
Role of Pharmacogenetics in the Treatment of Acute Myeloid Leukemia: Systematic Review and Future Perspectives.
Pinto-Merino Á et al.
Pharmaceutics, 2022
Genetics of Anthracycline-Associated Cardiotoxicity.
Al-Otaibi TK et al.
Frontiers in Cardiovascular Medicine, 2022
Molecular Profiling of Kenyan Acute Myeloid Leukemia Patients.
Gatua M et al.
Frontiers in Genetics, 2022
POLRMT as a Novel Susceptibility Gene for Cardiotoxicity in Epirubicin Treatment of Breast Cancer Patients.
Velasco-Ruiz A et al.
Pharmaceutics, 2021
Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform.
Kim B et al.
Translational and Clinical Pharmacology, 2021
Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia.
Megías-Vericat JE et al.
Pharmacogenetics and Genomics, 2021
An Example of Personalized Treatment in HR+ HER2+ Long Survivor Breast Cancer Patient (Case Report).
Panebianco M et al.
Current Oncology (toronto, Ont.), 2021
CBR3 V244M is associated with LVEF reduction in breast cancer patients treated with doxorubicin.
Lang JK et al.
Cardio-oncology (london, England), 2021
Decoding variants in drug-metabolizing enzymes and transporters in solid tumor patients by whole-exome sequencing.
Aboul-Soud MAM et al.
Saudi Journal of Biological Sciences, 2021
Clinically relevant endothelial nitric oxide synthase polymorphisms and their impact on drug response.
Cotta Filho CK et al.
Expert Opinion on Drug Metabolism & Toxicology, 2020
Genetic factors in anthracycline-induced cardiotoxicity in patients treated for pediatric cancer.
Petrykey K et al.
Expert Opinion on Drug Metabolism & Toxicology, 2020
The Identification of Admixture Patterns Could Refine Pharmacogenetic Counseling: Analysis of a Population-Based Sample in Mexico.
Martínez-Magaña JJ et al.
Frontiers in Pharmacology, 2020
Introducing the first whole genomes of nationals from the United Arab Emirates.
AlSafar HS et al.
Scientific Reports, 2019
Targeted next generation sequencing as a tool for precision medicine.
Gulilat M et al.
Bmc Medical Genomics, 2019
Analytical Validation of Variants to Aid in Genotype-Guided Therapy for Oncology.
Swart M et al.
The Journal of Molecular Diagnostics : Jmd, 2019
Pediatric Anthracycline-Induced Cardiotoxicity: Mechanisms, Pharmacogenomics, and Pluripotent Stem-Cell Modeling.
Tripaydonis A et al.
Clinical Pharmacology and Therapeutics, 2019
Complex roads from genotype to phenotype in dilated cardiomyopathy: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology.
Bondue A et al.
Cardiovascular Research, 2018
NOS3 895G>T and CBR3 730G>A Are Associated with Recurrence Risk in Non-Muscle-Invasive Bladder Cancer with Intravesical Instillations of THP.
Zhou Q et al.
Chemotherapy, 2018
Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trial.
Serie DJ et al.
Pharmacogenetics and Genomics, 2017
How gene polymorphisms can influence clinical response and toxicity following R-CHOP therapy in patients with diffuse large B cell lymphoma.
Falduto A et al.
Blood Reviews, 2017
Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events.
Meißner T et al.
Cold Spring Harbor Molecular Case Studies, 2017
Candidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A Systematic Review and Meta-analysis.
Leong SL et al.
Scientific Reports, 2017
Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing?
Magdy T et al.
Pharmacology & Therapeutics, 2016
Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines.
Hertz DL et al.
Pharmacogenomics, 2016
Pharmacogenetics driving personalized medicine: analysis of genetic polymorphisms related to breast cancer medications in Italian isolated populations.
Cocca M et al.
Journal of Translational Medicine, 2016
Single-nucleotide polymorphisms in reductase genes are not associated with response to daunorubicin-based remission induction.
Lubieniecka JM et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 2013
Correlation of aldo-ketoreductase (AKR) 1C3 genetic variant with doxorubicin pharmacodynamics in Asian breast cancer patients.
Voon PJ et al.
British Journal of Clinical Pharmacology, 2013
The relationship between changes in functional cardiac parameters following anthracycline therapy and carbonyl reductase 3 and glutathione S transferase Pi polymorphisms.
Volkan-Salanci B et al.
Journal of Chemotherapy (florence, Italy), 2012
Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group.
Blanco JG et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2012
Functional polymorphisms in xenobiotic metabolizing enzymes and their impact on the therapy of breast cancer.
Vianna-Jorge R et al.
Frontiers in Genetics, 2012
Pharmacogenetics of genes across the doxorubicin pathway.
Jamieson D et al.
Expert Opinion on Drug Metabolism & Toxicology, 2011
Pharmacogenomics of cardiovascular drugs and adverse effects in pediatrics.
Visscher H et al.
Journal of Cardiovascular Pharmacology, 2011
Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin.
Bains OS et al.
The Journal of Pharmacology and Experimental Therapeutics, 2010
Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism.
Bains OS et al.
The Journal of Pharmacology and Experimental Therapeutics, 2010
Chronic health conditions in childhood cancer survivors: is it all treatment-related--or do genetics play a role?
Armenian SH et al.
Journal of General Internal Medicine, 2009
Identification of the promoter of human carbonyl reductase 3 (CBR3) and impact of common promoter polymorphisms on hepatic CBR3 mRNA expression.
Zhang J et al.
Pharmaceutical Research, 2009
Pharmacogenetics in breast cancer therapy.
Tan SH et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2008
CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients.
Lal S et al.
Cancer Science, 2008
Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity.
Fan L et al.
Pharmacogenetics and Genomics, 2008
Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer.
Blanco JG et al.
Cancer, 2008